Back

Panel discussion - CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy: treatment effect in hereditary vs. wild-type disease

17 May 2025 (12:14 - 12:15)
Organised by: Logo
Congress Presentation Part of: Hottest trials and trial updates (1) Clinical HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

20 More presentations in this session

Presentation thumbnail
FINEARTS­HF: Blinded drug withdrawal
Doctor M. Vaduganathan (Boston, US)
Slides Video
Presentation thumbnail
Discussant review - FINEARTS-HF
Doctor M. Costanzo (Naperville, US)
Slides Video
Presentation thumbnail
Panel discussion - FINEARTS-HF
Video
Presentation thumbnail
FAIR-HF2 DZHK05: Efficacy of ferric carboxymaltose in heart failure and iron deficiency stratified by transferrin saturation
Professor S. Anker (Berlin, DE)
Slides Video
Presentation thumbnail
Discussant review - FAIR-HF2 DZHK05
Doctor V. Chopra (New Delhi, IN)
Slides Video

Access the full session

Session thumbnail
Hottest trials and trial updates (1)
Video

The Event

Event poster

Heart Failure 2025

17 May 2025 12:14 CET
You may be interested in
thumbnail
Congress Presentation
Gene editing: can CRISPR cure ATTR?
28 August 2026
thumbnail
Congress Presentation
Panel discussion - ODYSSEY-HCM and MAPLE-HCM
30 August 2025
thumbnail
Congress Presentation
Ask the Trialist - HELIOS-B
30 August 2024
thumbnail
Congress Presentation
Updates in gene therapy in heart failure and cardiomyopathies - discussion
10 May 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources